Skip to main content

ID-Week-2024-eventsID Week took place October 16-19 in Los Angeles, CA, the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.

UNC’s Division of Infectious Diseases was well represented at the event. Following is a listing of faculty investigators and their studies who presented posters and gave oral talks. To learn more, visit the online IDWeek Agenda.

ID-Week-2024-Posters
(L-R) Christopher Sellers, Joe Eron, Emily Sickbert-Bennett, Asher Schranz, Luther Bartelt and Natalie MacKow

POSTER SESSIONS

(P-258) A Longitudinal Study on the Impact of Sink Interventions on Environmental Bioburden and Patient Infections within Two Intensive Care Units at an Academic Hospital

  • Co-Authors: Emily Sickbert-Bennett, PhD, MS, CIC, FSHEA; Kevin Alby, PhD; David J. Weber, MD, MPH

(P-275) Risk Factors for Community Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacterales (ESCrE) among People with HIV in Botswana

  • Co-Author: Kevin Alby, PhD

(P-280) Risk Factors for Household Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacterales (ESCrE) in Botswana

  • Co-Author: Kevin Alby, PhD

(P-285) Effects of Comorbidities and Charlson Comorbidity Index Application on Patient Outcomes in Blood and Respiratory Carbapenem-Resistant Gram-Negative Bacterial Infections

  • Co-Author: David van Duin, MD, PhD

(P-430) Reason for Hospitalization Contrasting Adjudication versus ICD-10 Coding Among Person with HIV, 2016-2019

  • Presenting Author: Alex Commanday, MD
  • Co-Authors: Claire E. Farel, MD, MPH; Joseph J. Eron, MD; Sonia Napravnik, PhD

ID-Week-Natalie-McKow-CSellers
Natalie KcKow explains a poster to Christopher Sellers, John Franzone and Luther Bartelt.

 

(P-861) CTX-M-15 producing H30 ST131 Escherichia coli contributes to carbapenem use for E. coli bloodstream infections in the United States

  • Presenting Author: Natalie Mackow, MD
  • Co-Author: David van Duin, MD, PhD

(P-931) Characterizing Sex-Specific Trends in Opioid Use Disorder-Associated Infective Endocarditis in the United States from 2016-2020

  • Co-Author: Asher J. Schranz, MD, MPH

(P-1353) Molecular Heterogeneity of Stenotrophomonas maltophilia Isolates Associated with Human Infections in the US and Colombia

  • Co-Author: David van Duin, MD, PhD

(P-1797) Implementation of a Handshake Stewardship Pilot for Inpatient General Medicine Teams at an Academic Medical Center

  • Presenting Author: Joey Stromberg, MD
  • Co-Authors: Ashley H. Marx, PharmD; Nikolaos Mavrogiorgos, MD

ID-Week-AnneL-AsherS
Alex Commanday, Anne Lachiewicz and Asher Schranz

(P-1871) Surge Protector: Characterizing the Challenges of Fluctuating OPAT Volume

  • Presenting Author: Asher J. Schranz, MD, MPH
  • Co-Authors: Madison Ponder (PhD Candidate); Michael Smartwood, MSN, RN; Alan C. Kinlaw, PhD; Teresa Oosterwyk, RN; Angela Perhac, PharmD;  Ashley H. Marx, PharmD; Mary Catherine Bowman, MD, PhD; and Claire E. Farel, MD, MPH

(P-1874) Impact of Compromised Host AntimicRobial Management Service (CHARMS) on All Cause Readmission in Solid Organ Transplant Patients Discharged on Intravenous Antimicrobials

  • Co-Author: Luther A. Bartelt, MD; Anne Friedland, MD; Anne Lachiewicz, MD, MPH; Arlene C. Sena, MD, MPH; Tessa Andermann, MD, MPH; Elizabeth C. Arant, MD; Mary Catherine Bowman, MD, PhD; Zack Deyo, PharmD; David van Duin, MD, PhD; Brent W. Footer, PharmD

(P-2099) A Novel Anaerobic Activity Index to define the “anti-anaerobic) spectrum of antimicrobials

  • Presenting Author: Natalie Mackow, MD
  • Co-Authors: Luther A. Bartelt, MD; David van Duin, MD, PhD

(P-2320) Clinical Significance of Colonization with Fluoroquinolone-Resistant Enterobacterales in Hematopoietic Cell Transplant Recipients and Patients with Acute Leukemia

  • Co-Author: David van Duin, MD, PhD

(P-2326) The Under-recognized Burden of Lassa Virus Infection in Liberia

  • Co-Authors: David A. Wohl, MD; William A. Fischer II, MD

 

ID-Week-Thomas-Holowka
Thomas Holowka presenting during the session: Therapy for Carbapenem-Resistant Organisms in the Real World.

ORAL PRESENTATIONS

Session 12: Bills, Bill, Bills (and ID): What’s New and Exciting in Billing and Coding

  • Meet-the-Professor, Faculty on Panel: Asher J. Schranz, MD, MPH
  • Presentation 42: Practical methods to enhance ID physician Reimbursement
  • Speaker: Asher J. Schranz, MD, MPH

Session 25: Managing Infection in the Era of MDR, XDR and PDF Among Immunocompromised Hosts

  • Symposium Moderator: Tessa Andermann, MD, MPH

Session 32: Tackling Gram-Negative Infections in Health Care Settings

Presentation 101: Patients with Carbapenem-resistant Klebsiella aerogenes and Enterobacter cloacae complex Colonization or Infection Have Different Baseline Characteristics but Similar Mortality and Clinical Outcomes

  • Presenting Author: John P. Franzone, MD
  • Co-Authors: Tessa Andermann, MD, MPH; David van Duin, MD, PhD

Learning Lounge 1 Supported by Pfizer

  • Presentation: Innovations Driving Vaccine Evolution
  • Speaker: David J. Weber, MD, MPH

Session 105: In the Era of Shorter Is Better, Does the Data Apply to My Immunocompromised/Transplant Patient? A Critical Review of the Evidence

  • Presentation 250: Duration of treatment of Gram-negative bacteremia in immunocompromised patients
  • Speaker: David van Duin, MD, PhD

Session 105: In the Era of Shorter Is Better, Does the Data Apply to My Immunocompromised/Transplant Patient? A Critical Review of the Evidence

  • Meet-the-Professor Faculty on Panel: David van Duin, MD, PhD

Session 124: Therapy for Carbapenem-Resistant Organisms in the Real World

  • Presentation 311: Defining the magnitude of desirability of outcome ranking (DOOR) differences in effectiveness of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)
  • Co-Author: David van Duin, MD, PhD

Session 124: Therapy for Carbapenem-Resistant Organisms in the Real World

  • Presentation 312: Impact of Patient Subgroups on the Efficacy of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for Multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)
  • Co-Author: David van Duin, MD, PhD

Session 124: Therapy for Carbapenem-Resistant Organisms in the Real World

  • Presentation 315: Modeling Strain-Dependent Variability in Carbapenem-Resistant Klebsiella Pneumoniae Colonization in the Malnourished Host
  • Presenting Author: Thomas Holowka, MD, PhD
  • Co-Author: David van Duin, MD, PhD

Session 163: Public Health Medley: A Diverse Mix of Topics and Trends

  • Presentation 386: Pathogen-Harboring Ticks and prevalent in Suburban Green Spaces in Central North Carolina
  • Co-Author: Ross M. Boyce, MD, MSc

Session 253: Late Breaker Abstract Session: What’s Going Viral

  • Presentation 577: Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir
  • Co-Author: Joseph J. Eron, MD

 

Visit IDWeek to learn more.